AVNS Q4 2023: HA Portfolio Down 35% as Transformation Targets Margin Expansion
AVNS’s Q4 highlighted continued pricing pressure in its HA pain relief portfolio, driving a sharp segment decline, while transformation initiatives delivered margin and cash flow progress. Digestive health outperformed, but pain management remains a drag as leadership leans on commercial resets and cost discipline to hit 2025 targets. Execution on supply chain, portfolio rationalization, and cost takeout are central to the company’s bid for sustainable growth and free cash flow acceleration.
Summary
- HA Portfolio Headwind: Pricing pressure drove a steep pain management decline, challenging near-term growth.
- Cost Discipline Signals: Transformation initiatives are delivering margin gains and improved cash flow.
- 2025 Target Focus: Management remains committed to margin expansion and free cash flow ramp despite segment volatility.
Business Overview
AVNS (Avanos Medical) is a medical technology company specializing in products for digestive health and pain management and recovery. It generates revenue from devices and consumables sold to hospitals, surgical centers, and distributors, with major segments including Digestive Health (feeding tubes, CorePak, Neomed) and Pain Management and Recovery (HA injections, OnQ AMBIT, IVP, Game Ready, Trident RF).
Performance Analysis
Q4 results were marked by a steep drop in the company’s hyaluronic acid (HA) pain relief portfolio, which fell nearly 35% YoY for the full year and about 12% in Q4, excluding divested or discontinued products. This decline was driven primarily by Medicare reimbursement changes that pressured pricing, not volumes, resulting in a lower sales base for pain management and recovery. Digestive health provided a partial offset, growing double digits globally for the year, though Q4 growth slowed to 3% due to tough comps and distributor inventory rebalancing.
Transformation initiatives delivered tangible progress: adjusted gross margin held above 58% in Q4, and SG&A as a percentage of revenue improved sequentially for the fourth straight quarter. Supply chain execution reduced backorders from over $10 million to less than $2 million by year end, freeing working capital and supporting cash flow. Adjusted EBITDA margin improved 140 basis points YoY, reflecting cost takeout and portfolio optimization.
- HA Price Compression: Medicare-driven pricing cuts, not volume loss, drove the majority of pain management revenue decline.
- Digestive Health Resilience: CorePak and Neomed continued to deliver, with global double-digit growth for the year.
- Supply Chain Reset: Backorder reduction and inventory management improved working capital and operational reliability.
While sales underwhelmed in Q4, execution on cost, margin, and cash flow metrics supports management’s confidence in hitting 2025 financial targets, albeit from a lower revenue base.
Executive Commentary
"Although we are disappointed with our fourth quarter sales results, we were pleased with our overall execution, which was driven throughout the year by our three-year transformation priorities. This performance gives us confidence in our ability to be within the range of the 2025 financial targets we established last year during our investor day."
Joe Woody, CEO
"Overall, for the year, adjusted EBITDA margin improved to 14.7% compared to 13.3% in 2022, a 140 basis point increase year over year."
Michael Greiner, CFO & Chief Transformation Officer
Strategic Positioning
1. Pain Management Reset and Commercial Realignment
AVNS’s pain management and recovery business is undergoing a commercial reset after Medicare reimbursement changes led to outsized pricing pressure in the HA portfolio. Leadership is focused on disciplined pricing, stabilizing volumes, and leveraging cross-selling with surgical pain and DEROS products to restore growth by 2025.
2. Digestive Health as Growth Engine
Digestive Health is now the company’s most reliable growth driver, benefiting from innovation (CorePak, Neomed) and expansion into new global markets. Product launches in the back half of 2024 are expected to sustain or accelerate performance, with management targeting mid- to high-single-digit organic growth.
3. Portfolio and Cost Transformation
Portfolio rationalization (divestitures, exits from low-margin products) and cost discipline (headcount, process optimization) are central to margin expansion. SG&A reductions and supply chain improvement are supporting a path to 38-39% SG&A as a percent of revenue by 2025, with gross margin targeted above 60%.
4. Capital Allocation Discipline
AVNS maintains a strong balance sheet with low leverage, supporting both bolt-on M&A and opportunistic share repurchases. Leadership sees room for a strategic acquisition in 2024 without compromising operational execution or capital return.
5. Free Cash Flow Focus
Free cash flow generation is a top priority, with working capital improvement (especially inventory reduction) and lower one-time charges expected to drive FCF toward $100 million in 2025.
Key Considerations
AVNS’s quarter was defined by resilience in digestive health, sharp pain management headwinds, and visible progress on transformation levers. The company’s ability to deliver on margin and cash flow targets will depend on execution in several areas:
Key Considerations:
- HA Portfolio Stabilization: Price pressure from Medicare changes will persist into mid-2024, but management expects stabilization by year end and growth in 2025 if pricing normalizes and commercial resets gain traction.
- Digestive Health Innovation: New product launches and market expansion are critical to offsetting pain management declines and sustaining above-market growth.
- Cost Takeout and Margin Expansion: Continued SG&A discipline and supply chain improvement underpin the path to 2025 margin targets.
- Capital Allocation Flexibility: Strong liquidity enables both M&A and share buybacks, but execution risk remains if bolt-ons distract from core transformation priorities.
- Working Capital Execution: Inventory reduction and backorder management are essential to unlocking free cash flow potential.
Risks
Medicare reimbursement volatility remains the principal risk, especially for the HA portfolio, where further pricing cuts or competitive responses could undermine stabilization efforts. Execution risk is elevated as the company juggles transformation, commercial resets, and new product launches. Digestive health growth could moderate if innovation or market expansion under-delivers. Macro headwinds, distributor inventory swings, or supply chain disruptions could further impact results.
Forward Outlook
For Q1 2024, AVNS expects a slow start, with acceleration in the back half of the year as transformation benefits build. Guidance for 2024:
- Revenue: $685 million to $705 million (mid-single-digit organic growth)
- Adjusted gross margin: 59.5% to 60.5%
- SG&A as % of revenue: 41% to 42%
- Adjusted EPS: $1.30 to $1.45
- Adjusted EBITDA margin: at least 200 basis points improvement
For full-year 2025, management reaffirmed margin and free cash flow targets but acknowledged the revenue base will be lower than initially forecast due to HA declines:
- Organic revenue: mid-single-digit growth (off a lower base)
- Gross margin: surpassing 60%
- SG&A: 38-39% of revenue
- Free cash flow: approximately $100 million
Management expects stronger performance in the second half of 2024, driven by new product launches and further cost improvements.
- HA pricing expected to stabilize by year end
- Digestive health launches to sustain growth
Takeaways
AVNS is navigating a tough segment reset while making visible progress on transformation, margin, and cash flow imperatives. The path to 2025 targets is intact, but execution risk remains elevated given ongoing HA headwinds and the need for digestive health to sustain its outperformance.
- Pain Management Drag: HA portfolio will weigh on growth until pricing stabilizes, but commercial resets and cross-selling could restore momentum by 2025.
- Transformation Progress: Cost takeout, supply chain fixes, and portfolio optimization are driving margin and cash flow improvement.
- Watch Digestive Health: Sustained innovation and global expansion must deliver to offset pain management volatility and support long-term growth.
Conclusion
AVNS’s Q4 underscored the challenges of segment-specific headwinds amid broader transformation. Margin and cash flow execution are bright spots, but the company’s ability to deliver on its 2025 commitments will hinge on both commercial stabilization in pain management and continued outperformance in digestive health.
Industry Read-Through
Medtech peers exposed to U.S. reimbursement risk, especially in pain management and orthopedics, face similar pricing pressures as seen in AVNS’s HA portfolio. The quarter highlights the importance of portfolio rationalization and cost discipline as margin levers in a slower growth environment. Distributors’ inventory swings and supply chain normalization are industry-wide themes, with working capital management emerging as a differentiator for free cash flow. Innovation in core categories and the ability to offset reimbursement-driven declines with new products or channels will remain a key test for all device makers in 2024 and beyond.